Cencora Inc. (COR) Q1 2026 (USD) EPS 4.08 (exp. 4.05), Revenue 85.9bln (exp. 86.06bln); FY Outlook: Adj. EPS 17.45-17.75 (exp. 17.61)

• Adjusted operating income guidance has been raised to growth of 11.5% to 13.5% (prev. 8% to 10%) primarily to reflect the completion of the acquisition of OneOncology and the performance of the U.S. Healthcare Solutions segment.

Cencora Inc. reported a slight beat on EPS expectations, which is positive, but revenue came in short of forecasts, suggesting potential weakness in sales momentum. Importantly, the revised FY outlook with improved operating income growth guidance reflects confidence in the recent acquisition and the healthcare segment's performance, which could bolster investor sentiment and support the stock price in the near term.